Although network pharmacology and in vivo experiments confirmed JAK/STAT as a signaling pathway for LC treatment by QSFZQL, relevant in vitro experimental validation is still lacking, and the network pharmacology revealed that QSFZQL targeting AKT1, STAT3, JUN, IL-6 and MAPK3 intervened to inhibit the proliferation of lung adenocarcinoma needs to be confirmed by further experiments. Here, IL6 is linked to laryngotracheoesophageal cleft.